Dimensional Fund Advisors LP Has $14.66 Million Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Dimensional Fund Advisors LP raised its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 79.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 109,560 shares of the company’s stock after buying an additional 48,590 shares during the quarter. Dimensional Fund Advisors LP owned 0.37% of Inspire Medical Systems worth $14,663,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in INSP. Van ECK Associates Corp boosted its position in shares of Inspire Medical Systems by 7.5% in the second quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock worth $138,000 after buying an additional 72 shares during the period. Bessemer Group Inc. boosted its position in Inspire Medical Systems by 1.2% during the 1st quarter. Bessemer Group Inc. now owns 8,475 shares of the company’s stock worth $1,820,000 after acquiring an additional 100 shares during the period. Gilliland Jeter Wealth Management LLC grew its stake in Inspire Medical Systems by 0.8% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 15,508 shares of the company’s stock valued at $2,075,000 after acquiring an additional 125 shares in the last quarter. SouthState Corp acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at about $27,000. Finally, American Trust lifted its position in shares of Inspire Medical Systems by 14.2% in the first quarter. American Trust now owns 1,905 shares of the company’s stock worth $409,000 after purchasing an additional 237 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Up 4.8 %

Shares of Inspire Medical Systems stock opened at $214.93 on Friday. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40. The stock has a 50 day moving average price of $190.48 and a two-hundred day moving average price of $182.98. The stock has a market capitalization of $6.39 billion, a P/E ratio of -390.78 and a beta of 1.34.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.46. Inspire Medical Systems had a net margin of 0.85% and a return on equity of 1.03%. The business had revenue of $195.89 million during the quarter, compared to the consensus estimate of $189.08 million. During the same period in the prior year, the firm earned ($0.41) EPS. Inspire Medical Systems’s quarterly revenue was up 29.6% compared to the same quarter last year. Sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the sale, the director now owns 23,140 shares of the company’s stock, valued at $5,090,800. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, insider Randy Ban sold 4,861 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the completion of the transaction, the insider now owns 3,056 shares of the company’s stock, valued at approximately $576,208.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the sale, the director now directly owns 23,140 shares in the company, valued at approximately $5,090,800. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,692 shares of company stock worth $1,099,207 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

INSP has been the topic of a number of research analyst reports. KeyCorp lowered their price objective on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Morgan Stanley dropped their price target on shares of Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research note on Monday, July 15th. Truist Financial restated a “buy” rating and issued a $240.00 target price (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Robert W. Baird cut their price target on Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Stifel Nicolaus lowered their price target on Inspire Medical Systems from $210.00 to $170.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $216.62.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.